Skip to main content

Table 4 Anti-CCP titer decrease in adalimumab treated patients: correlation with the clinical response to treatment

From: Adalimumab clinical efficacy is associated with rheumatoid factor and anti-cyclic citrullinated peptide antibody titer reduction: a one-year prospective study

ACR response, week 24 Week 0 Week 24 P ACR response, week 48 Week 0 Week 48 P
<20% (n = 6) 118.4 ± 34.9 111.8 ± 48.8 n.s. <20% (n = 3) 107 ± 14.1 68.4 ± 23.3 n.d.
ACR 20 (n = 21) 111.5 ± 45.9 104.3 ± 48.5 n.s. ACR 20 (n = 21) 121.8 ± 48.2 88.6 ± 52.6 0.001
ACR 50 (n = 16) 121.9 ± 45.1 93.9 ± 46.4 0.001 ACR 50 (n = 13) 119.6 ± 45.8 73.5 ± 36.2 0.001
ACR 70 (n = 3) 126.8 ± 51.9 85.9 ± 43.5 n.d. ACR 70 (n = 9) 105.3 ± 37.7 65.3 ± 35.5 0.003
  1. 46 anti-CCP-positive patients at baseline were included in the evaluation. Results are means ± SD. CCP, cyclic citrullinated peptide; n.d., not done; n.s., not significant.